IN THE SPECIFICATION:

Please further amend the first paragraph on page 4, line 10 to page 6, line 11, as follows:

(Currently amended): In another aspect of the invention there is provided an inhibitor of ras farnesylation of Formula I

wherein:

R^1 is selected from H; -C_{1-4}alkyl; -C_{1-3}alkylene-Ph optionally mono or di-substituted on Ph with substituents selected from C_{1-4}alkyl, halogen, OH, C_{1-4}alkoxy, C_{1-4}alkanoyl, C_{1-4}alkanoyloxy, amino, C_{1-4}alkylamino, di(C_{1-4}alkyl)amino, C_{1-4}alkanoylamino, nitro, cyano, carboxy, carbamoyl, C_{1-4}alkoxycarbonyl, thiol, C_{1-4}alkylsulfanyl, C_{1-4}alkylsulfinyl, C_{1-4}alkylsulfonyl and sulfonamido; -CO-C_{1-4}alkyl; -CO-O-C_{1-4}alkyl; -CO-O-C_{2-4}alkenyl; -CO-O-$(CH_2)_n$Ph optionally substituted on Ph as defined for substitution on Ph in R^1 = -C_{1-3}alkylene-Ph above and n=0-4;

-C_{1-4}alkylene-CONR^{4}R^5 where R^4 & R^5 are independently selected from H and C_{1-4}alkyl; and -C_{1-4}alkylene-COOR^6 where R^6 is selected from H, C_{1-4}alkyl;

R^2 is selected from H; -C_{1-4}alkyl; -C_{1-3}alkylene-Ph optionally substituted on Ph as defined for substitution on Ph in R^1 = -C_{1-3}alkylene-Ph above; -COC_{1-4}alkyl; and -COOC_{1-4}alkyl;

R^3 is selected from H; OH; CN; CF_3; NO_2; -C_{1-4} alkyl; -C_{1-4}alkylene-R^7 where R^7 is selected from phenyl, naphthyl, a 5-10 membered monocyclic or bicyclic heteroaryl ring containing up to 5 heteroatoms selected from O, N and S and any aryl ring in R^7 is optionally substituted as defined for substitution on the Ph group in R^1 = -C_{1-3}alkylene-Ph above; R^7; C_{2-4}alkenyl; halogen; -$(CH_2)_y$COOR^8 where y= 0-3 and R^8 represents H, C_{1-4}alkyl, or C_{2-4}alkenyl; -CONR^{9}R^{10} where R^9 and R^{10} independently represent H, C_{1-4}alkyl, C_{2-4}alkenyl, -O-C_{1-4}alkyl, -O-C_{2-4}alkenyl, -C_{1-3}alkylenePh optionally substituted as defined for this group for R^1 above; -CON(R^{11})OR^{12} where R^{11} and R^{12} independently represent H, C_{1-4}alkyl and C_{2-4}alkenyl;

a group of Formula II, -CONR^{13}-CHR^{14}-COOR^{17} , where R^{13} is H or C_{1-4}alkyl, R^{17} is H or C_{1-6}alkyl, R^{14} is selected from the side chain of a lipophilic amino acid,

carbamoylC_{1-4}alkyl, N-(monoC_{1-4}alkyl)carbamoylC_{1-4}alkyl and N-(diC_{1-4}alkyl)carbamoylC_{1-4}alkyl, the group of Formula II having L or D configuration at the chiral alpha carbon in the corresponding free amino acid; a lactone of formula



;

C_{1-4}alkyl monosubstituted on carbon with =N-OH;

a group of Formula -X-R^{15} where X is selected from O, CO, CH_2, S, SO, SO_2 and R^{15} is selected from C_{1-6}alkyl, phenyl, naphthyl, a 5-10 membered monocyclic or bicyclic heteroaryl ring containing up to 5 heteroatoms selected from O, N and S and any aryl ring in R^{15} is optionally substituted as defined for the Ph group in R^1 = -C_{1-3}alkylene-Ph;

p is 0-3 in which R^3 values can be the same or different;

G is a linking moiety selected from the following groups written from left to right in Formula I:

-CO-NR^{16}- where R^{16} is selected from H, C_{1-4}alkyl, C_{1-4}alkylene-Z, -CO-C_{1-4}alkylene-Z, -CO-C_{1-6}alkyl, -COZ, Z and Z is selected from -O-C_{1-4}alkyl, phenyl, naphthyl, a 5-10 membered monocyclic or bicyclic heteroaryl ring containing up to 5 heteroatoms selected from O, N and S and any aryl ring in R^{16} is optionally substituted as defined for the Ph group in R^1 = -C_{1-3}alkylene-Ph; -CH_2-NR^{18}- where R^{18} represents any value defined for R^{16}; -CH_2S-; -CH_2O-; -CH_2-CHR^{19}- where R^{19} represents any value defined for R^{16}; -CH=CR^{20}- where R^{20} represents any value defined for R^{16}; -CH_2NR^{21}-T- where R^{21} represents any value defined for R^{16}, T represents -$(CH_2)_w$- where w is 1-4 and T is optionally monosubstituted with R^{22} where R^{22} represents any value for R^{16} other than H; -CH_2NR^{23}-SO_2- where R^{23} represents any value defined for R^{16}; ~~-CH_2-NR^{24}-CO-T-~~ -CH_2-NR^{24}-CO-T^1- where R^{24} represents any value defined for R^{16}, ~~T~~ T^1 represents ~~-$(CH_2)_w$-~~ -$(CH_2)_{w^1}$- where ~~w~~ w^1 is 0-4 and ~~T~~ T^1 is optionally monosubstituted with R^{29} where R^{29} represents any value for R^{16} other than H; -CO-NR^{25}-T- where R^{25} represents any value defined for R^{16}, T represents -$(CH_2)_w$- where w is 1-4 and T is optionally monosubstituted with R^{26} where R^{26} represents any value for R^{16} other than H; -CH_2S-T- where T represents -$(CH_2)_w$- where w is 1-4 and T is

optionally monosubstituted with R^{27} where R^{27} represents any value for R^{16} other than H;

$-CH_2O-T-$ where T represents $-(CH_2)_w-$ where w is 1-4 and T is optionally monosubstituted with R^{28} where R^{28} represents any value for R^{16} other than H;

A is selected from phenyl; naphthyl; a 5-10 membered monocyclic or bicyclic heteroaryl ring containing up to 5 heteroatoms where the heteroatoms are independently selected from O, N & S;

or a -S-S- dimer thereof when R^2=H; or a N-oxide thereof;

or an enantiomer, diastereoisomer, pharmaceutically acceptable salt, prodrug or solvate thereof.